Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma

(2015) BENJAMIN M. ELLINGSON et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients

(2015) Myron Zhang et al.   NEURO-ONCOLOGY

Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria)

(2014) Nikdokht Farid et al.   JOURNAL OF NEURO-ONCOLOGY

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab

(2014) Rifaquat Rahman et al.   JOURNAL OF NEURO-ONCOLOGY

NI-64 * 3D-PRINTED MRI-BASED CUSTOM BRAIN MOLDS FOR MINIMIZING TISSUE DISTORTION AND PRECISELY SLICING TISSUE FOR CO-REGISTRATION WITH CLINICALLY ACQUIRED MRI IN GLIOMA PATIENTS

(2014) B. Pellatt et al.   NEURO-ONCOLOGY

Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma

(2014) Peter S. LaViolette et al.   NEURO-ONCOLOGY

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma

(2014) K. M. Schmainda et al.   NEURO-ONCOLOGY

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma

(2014) O. Bahr et al.   NEUROLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging

(2013) Eui Jin Hwang et al.   JOURNAL OF NEURO-ONCOLOGY

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma

(2013) Peter S. LaViolette et al.   NEURO-ONCOLOGY

Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM

(2013) Nikdokht Farid et al.   Frontiers in Oncology

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

(2012) S. Mong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma

(2012) B. M. Ellingson et al.   NEURO-ONCOLOGY

Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma

(2011) A. Gupta et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia?

(2010) Johannes Rieger et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Exacerbation of Cerebral Radiation Necrosis by Bevacizumab

(2010) Deva Sanjeeva Jeyaretna et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging—Pilot Study

(2010) Rahul N. Sawlani et al.   RADIOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

(2009) Johannes Rieger et al.   JOURNAL OF NEURO-ONCOLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival

(2008) Daniel A. Hamstra et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY